Literature DB >> 25957453

Aligning incentives to fulfil the promise of personalised medicine.

Victor J Dzau1, Geoffrey S Ginsburg2, Karen Van Nuys3, David Agus4, Dana Goldman5.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25957453      PMCID： PMC6481305          DOI： 10.1016/S0140-6736(15)60722-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  21 in total

1.  Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine.

Authors:  Giovanni Di Minno; Elena Tremoli
Journal:  Haematologica       Date:  2017-02-28       Impact factor: 9.941

Review 2.  Finding the right balance between precision medicine and personalized care.

Authors:  Finlay A McAlister; Andreas Laupacis; Paul W Armstrong
Journal:  CMAJ       Date:  2017-08-21       Impact factor: 8.262

Review 3.  Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing.

Authors:  Deborah Cragun; Anita Y Kinney; Tuya Pal
Journal:  Expert Rev Mol Diagn       Date:  2016-12-13       Impact factor: 5.225

Review 4.  Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?

Authors:  Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman
Journal:  Addiction       Date:  2017-04-21       Impact factor: 6.526

5.  The evolution of patient-specific precision biomarkers to guide personalized heart-transplant care.

Authors:  Mario C Deng
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-10-28

6.  Pragmatic medicine in solid cancer: a translational alternative to precision medicine.

Authors:  Jan Brábek; Daniel Rosel; Michael Fernandes
Journal:  Onco Targets Ther       Date:  2016-04-05       Impact factor: 4.147

Review 7.  Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?

Authors:  Effie Liakopoulou; Alexander Knuth
Journal:  Viszeralmedizin       Date:  2015-12-04

Review 8.  Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.

Authors:  Samantha Kass Newman; Raj K Jayanthan; Grant W Mitchell; Jossie A Carreras Tartak; Michael P Croglio; Alexander Suarez; Amy Y Liu; Beatrice M Razzo; Enny Oyeniran; Jason R Ruth; David C Fajgenbaum
Journal:  Yale J Biol Med       Date:  2015-11-24

Review 9.  The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis.

Authors:  Gareth J Hollands; David P French; Simon J Griffin; A Toby Prevost; Stephen Sutton; Sarah King; Theresa M Marteau
Journal:  BMJ       Date:  2016-03-15

10.  Protocol for the development of a CONSORT-equity guideline to improve reporting of health equity in randomized trials.

Authors:  Vivian Welch; J Jull; J Petkovic; R Armstrong; Y Boyer; L G Cuervo; Sjl Edwards; A Lydiatt; D Gough; J Grimshaw; E Kristjansson; L Mbuagbaw; J McGowan; D Moher; T Pantoja; M Petticrew; K Pottie; T Rader; B Shea; M Taljaard; E Waters; C Weijer; G A Wells; H White; M Whitehead; P Tugwell
Journal:  Implement Sci       Date:  2015-10-21       Impact factor: 7.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.